- Open Access
Is total hip arthroplasty safely performed in lung transplant patients? Current experience from a retrospective study of the Zurich lung transplant cohort
© The Author(s). 2016
- Received: 14 April 2016
- Accepted: 30 June 2016
- Published: 15 July 2016
In recent years, the number of lung transplants has increased rapidly, with higher quality of life and improved survival rates in transplant recipients, including patients with advanced age. This, in turn, means that more transplant recipients will seek musculoskeletal care to treat degenerative joint disease and also trauma incidents. Safety concerns regarding elective and posttraumatic hip arthroplasty in transplant patients include an increased risk of infection, wound healing problems, periprosthetic fractures and loosening of the implants.
Clinical outcomes and safety aspects were retrospectively reviewed for five primary total hip arthroplasties (THA) in lung transplant recipients with minimal follow-up of two years at average of 2.6 (2–11) years. Patients were recruited from the Zurich Lung Transplant Center comprising of a cohort of 253 patients between January 1st, 2004 and December 31st, 2013.
All five patients subjectively reported excellent outcomes after THA with a final average Harris Hip Score of 97 (86–100). One 71-year-old patient died 26 months after THA unrelated to arthroplasty. One superficial wound healing disturbance was documented. No periprosthetic fractures, no dislocations, no periprosthetic infections, no further revision surgery, no implant loosening was observed.
In conclusion, THA can be safely and successfully performed even in lung transplant patients under long-term immunosuppressive therapy and polymedication, provided a multidisciplinary approach can be granted.
- Hip arthroplasty
- Lung transplantation
- Antibiotic treatment
In recent years, the number of lung transplants has increased rapidly, with improved survival rates in transplant recipients, including patients with advanced age . Lung transplant patients require triple life-long immunosuppression with steroids, as well as immunosuppressive agents preventing graft rejection. These medications have distinct side effects and can complicate medical and surgical treatment.
Lung transplant patients are vulnerable to medical complications also affecting the musculoskeletal system [1, 2]. Long-lasting and high-dose steroid use can lead to symptomatic osteonecrosis of the bones, particularly the femoral head [3–5]. Severe osteonecrosis can lead to subchondral fractures and collapse of the femoral head following total hip arthroplasty (THA) . Despite the risks of complications associated with lung transplants and other solid organ transplants, the number of transplants continues to rise, and with it, regardless of immunosuppression, an improved post-transplant quality of life and better chances of long-term survival. This, in turn, means that more transplant recipients will seek musculoskeletal care to treat degenerative joint disease and also (osteoporotic) trauma incidents.
Safety concerns regarding elective and posttraumatic arthroplasty in transplant patients include the potential risk of perioperative complications, especially an increased risk of infection and wound healing problems due to life-long immunosuppression [5–7]. There is also an increased risk of periprosthetic fractures and loosening, due to osteoporosis and secondary bone loss [2, 8–10].
With regard to transplant patients, it is still under debate which special medical and surgical management approaches could benefit from closer inspection.
Outcomes of THA have been reported in cardiac [6, 11, 12], liver [6, 7, 13–16], and mostly in renal transplants [5–7, 13, 17–25]. In the literature, there are few guidelines regarding particular perioperative precautions and postoperative care after hip arthroplasty in lung transplant patients [26, 27].
The purpose of this review was to examine the perioperative workup and outcome of THA in lung transplant recipients in the Zurich cohort.
Hospital stay d
Subjective hip value %
Harris Hip Score (HHS) points
CYA, MMF, PRED
CYA, MMF, PRED
TZP, TEC, CIP
Wound healing disturbance
CYA, MMF, PRED
TEC, MER (INN)
CYA, MMF, PRED
TZP, TEC, CIP
CYA, MMF, PRED
All patients were prepared well in advance for the THA by their lung transplant specialists. Patients underwent extensive cardiopulmonary testing, in-depth anaesthesia assessment and specific infectious disease workup. They were evaluated for their specific risks due to previous infectious issues including chronic bacterial and viral infections. In general, preoperative IV antibiotic treatment was initiated at least 24 h prior to surgery. Mostly, a dual regimen of piperacillin/tazobactam and teicoplanin was used empirically.
Patients continued on their transplantat-specific, mostly triple immunosuppressant regimen of the following drugs: cyclosporine, mycophenolic acid and corticosteroid pre- and postoperatively. In addition, patients were kept on their usual prophylactic antibiotic (pneumocystis pneumonia (PCP)), antiviral and antifungal agents.
Extremity preparation within the operative suite under laminar flow included electric clipping of hair, three-fold antiseptic scrub with alcohol disinfectant, followed by draping with sterile adhesive polyurethane film (Opsite). Two experienced orthopedic surgeons performed the procedures.
Following surgery, the patients were observed in IMCU or ICU. Postoperative antibiotic prophylaxis was given at least until wound healing confirmed. All patients received standard deep vein thrombosis prophylaxis, including compression stockings and low-molecular weight heparin, continuing for 6 weeks after operation.
Clinical and radiological follow-ups were obtained after 6 weeks, 3, 6, 12 and 24 months by the orthopaedic surgeons, in cooperation with their lung transplant specialists. All multidisciplinary patient charts related to the arthroplasty were analysed. Specific outcome measures included VAS, validated functional Harris Hip Score (HHS), subjective hip value, gait function and complications. All patients had a minimal follow-up of 24 months.
The Institutional Review Board approved the study (KEK-ZH-Nr. 2011–0320).
Between 2004 and 2013, five primary THAs were performed in 4 females and 1 male lung transplant recipients. Age at transplant was 36.2 (14.2–66.5) years. Three patients with avascular necrosis (AVN) of the femoral head presented markedly limited hip function with severe pain that failed to improve with conservative treatment. One patient suffered from the cut-out of cancellous screws through the femoral head, due to posttraumatic AVN after osteosynthesis of a femoral head fracture with three cannulated cancellous screws. One patient presented a pathologic femoral neck fracture caused by enchondroma. Hence, there was a time interval of 9.4 (2.4–12.2) years between lung transplant and THA. Arthroplasty was performed at an average age of 47.2 (23.6–69.0) years.
All five patients demonstrated relevant medical issues and preoperative comorbidities. ASA physical status was an average value of 2.8 (2–4). Most commonly, the patients suffered from chronic lung allograft dysfunction (CLAD), hypertension, diabetes mellitus, pancreatic insufficiency, chronic kidney disease, chronic transplant rejection and chronic infections (chronic cytomegalovirus (CMV) infection, chronic carrier Noro-virus (3 patients), throat swap multi drug-resistant Pseudomonas (1 patient)).
During hospital stay all patients received prolonged prophylactic antibiotic treatment with different medication over 21 (3–35) days. All patients had thromboembolic prophylaxis for six weeks. The postoperative course was complicated in one patient with difficult wound healing with development of a subcutaneous fistula of the absorbable suture after 11 weeks (77 d) requiring operative superficial revision of soft tissue. Length of hospital stay was 11 (7–39) days. No periprosthetic fractures, no dislocations, no periprosthetic infections, no further revision surgery, no implant loosening were observed (Fig. 1). One 71-year-old patient died 26 months after THA unrelated to arthroplasty.
Clinical and radiological follow-up postoperatively was available at an average of 2.6 (2–11) years. All patients were very satisfied and self-reported their subjective hip value of 100 (90–100) %. Average Harris Hip Score was 97 (86–100) points. One patient suffered from mild peritrochanteric pain, without limping.
As the number of patients undergoing lung transplantation increases, there will be a higher frequency of arthroplasties for osteonecrosis, trauma or degenerative osteoarthritis, in order to improve quality of life of transplant recipients.
Perioperative management requires a multidisciplinary approach of trained orthopedic surgeons, lung transplant specialists and specialized anaesthesiologists. It is our policy to directly involve the lung transplant team during the whole hospital stay in the perioperative care of these complex patients.
We observed a low incidence of hip arthroplasty (5 THA in 253 lung transplantations) over a period of 10 years at the Zurich Lung Transplant Cohort that is probably due to the meticulous and close follow-up management of lung transplant patients at our Institution. Furthermore, adaptation of immunosuppression for each individual lung transplant patient is mandatory to titrate to the lowest dose of the immunosuppression to prevent allograft rejection, however, avoid overimmunosuppression causing infection and poor wound healing. Cyclosporine A, mycophenolate mofetil and prednisone were predominantly used. All patients were prescribed daily medication between 5 and 7.5 mg prednisone accordingly 0.1–0.15 mg/kg/day beyond 12 months after transplantation . The risk of osteonecrosis is less than 3 % when the dosage is kept below 15 mg of prednisone per day [12, 28]. Immunosuppressive drugs such as cyclosporine A help to decrease the risk of avascular necrosis . In the literature, prevalence of osteonecrosis of the femoral head after organ transplantation ranges between 2 and 41 % [4, 5, 29]. Potential reasons for this wide variation are differences in steroid regimens and in the sensitivities of screening modalities including inability to capture data (MRI) on asymptomatic patients. However, the authors are unable to estimate the true incidence of femoral head necrosis in the patient cohort of lung transplant recipients. Otherwise, corticosteroids and immunosuppressive medication cause osteoporosis . The loss of bone mineral density (BMD) is most evident in the first year after transplantation, with a fracture rate up to 29 %  when high doses of steroids and immunosuppressives are needed to prevent acute organ rejection [8–10]. Most common fracture sides are vertebral compression fractures . In our cohort, we observed one femoral fracture after a cycling accident 6.4 years after lung transplantation, and one pathological fracture after three years because of benign enchondroma in the femoral neck. Our prophylactic medication augmenting bone density includes mainly calcium and vitamin D supplementation, and bisphosphonates based on bone mineral density assessment.
To prevent postoperative infection in patients with triple immunosuppression is of major importance. In our collective, there was one case of superficial wound healing disturbance. After 11 weeks, the patient suffered from small subcutaneous fistula of absorbable suture and was treated with operative spindle-shaped incision followed by an extended course of intravenous antibiotics. The literature reports a higher incidence of periprosthetic infection in transplant patients, with rates varying from no increase, to rates up to 19 % infections in various publications [5, 7, 25]. Vergidis et al. report 12 periprosthetic joint infections in 365 patients (3.4 %) . Most data is mostly available from renal transplant patients. Ledford et al. reported in his collective of 15 THA in 10 lung transplant recipients, no periprosthetic infections or revision surgeries .
Wide variance of results and small patient populations make it difficult to establish a definitive consensus of antibiotic treatment in these immunocompromised patients. In the literature, no guidelines regarding type and duration of antibiotic treatment exist. In some studies, antibiotic prophylaxis with cephalosporines was used predominantly for 24 h [14, 26]. In one other study, antibiotic prophylaxis was mainly cephalosporines or vancomycin over 6 weeks . We strongly support prolonged appropriate antibiotic treatment until entire wound healing occurs. Teicoplanin, piperacillin and ciprofloxacin were predominantly used in combination. Drug interaction with immunosuppression and potential side effects should be carefully considered . Duration of postoperative antibiotic treatment averaged 21 (3–35) days. Preoperative intravenous antibiotic treatment was started at least 24 h before surgery.
In our case series, the transfusion rate was very high. Despite the intraoperative blood loss being an average of 400 mL, during the postoperative course four patients received a blood transfusion for symptomatic anemia between the first and 5th postoperative day. The decision to transfuse was based on clinical symptoms and in conjunction with the recommendation by the lung transplant team. First hemoglobin after 24 h counted on average 98 (72–113) gL. High frequency of blood transfusions likely reflects the relative inability of lung transplant patients to tolerate a combination of fluid imbalance and minor fluctuations in hemoglobin levels postoperatively, because of restricted pulmonary function due to impaired lymphatic drainage. Furthermore, preoperative chronic anemia (hemoglobin 123 gL), low body weight (51 kg) and low BMI (19.7 kg/m2) in our population in combination with the expected intraoperative blood loss, may result in increased postoperative need for blood transfusion. Patients received, on average 2 units of blood. Other studies report a transfusion rate of 66 % in lung transplant patients  and lower rates (39 %) in liver transplant patients  after THA. We assume that a low threshold for transfusion is important in this special population, given the inability of lung transplant recipients to tolerate even minor fluctuations in hemoglobin levels postoperatively.
Perioperative precautions relating to arthroplasty in lung transplant patients (adapted from Schuurmans et al. )
Exhaustion of conservative treatment, interdisciplinary approval of operative treatment, “No standard indications for non-standard patients!”
Meticulous preparation of procedure with all involved specialists that may be relevant (including lung transplant specialist, experienced surgeon, specialized anesthetist, experienced intensive care physician for possible postoperative care)
Additional intravenous anti-infective treatment for at least one day before and prolonged after arthroplasty
Early and consequent laxative treatment to prevent intestinal complications. Avoid opioids.
Cautious blood pressure control and accurate fluid management. Arterial hypertension is highly prevalent among lung transplant patients. Preoperatively no restricted fluid intake to avoid hemodynamic instability and renal dysfunction. Fluid overload should be avoided intra-operatively due to impaired lymphatic drainage
Low threshold for transfusion postoperatively
Strict anti-reflux measures to prevent gastro-esophageal reflux and aspiration
Preventive strategies including intensive care unit bed ‘on standby’ after surgery
Anticipation of high likelihood of possible complications (kidney failure, hematoma, wound healing disturbance, delirium
In our cohort, one 71-year-old patient died 26 months after THA (4.6 years after lung transplantation) because of progressive CLAD. The only publication from Ledford et al. of a lung transplant patient cohort with THA reported a high mortality rate in 3 patients (33 %) at time of follow-up after 27.5 months . It is difficult to draw specific conclusions based on these data due to the shortened life expectancy could be related to other medical comorbidities and small patient cohort.
To the authors’ knowledge, there are no reports in the literature of THA in lung transplant patients using minimal-invasive anterior approach. In two of our cases, we used this anterior “Modified Hueter” approach without any difficulties intra-operatively. Special care requires precise exposure of the femoral entrance after capsular release avoiding periprosthetic shaft and greater trochanteric fractures due to poor bone quality.
Another controversial technical issue is THA fixation in lung transplant recipients . Generally, patients require triple life-long immunosuppression including steroids. Prolonged corticosteroid use is a significant risk factor for periprosthetic fractures and loosening of the implants due to osteoporosis and secondary bone loss [2, 8–10, 28]. Cemented acetabular and femoral components were used based on intraoperative assessment of weakened bone that will not allow press-fit technique. Since this was the case in all our patients, we cemented all acetabular components; in fact, in one additional patient, an acetabular roof reinforcement ring with hook was used. Femoral stems were uncemented in 3 cases and cemented in 2 procedures. We believe in the benefit of cemented implants, especially in the acetabulum, because of the perpetual steroid medication. Intraoperative acetabular and femoral fractures have to be avoided. Regarding cemented THA, Goffin et al. report on revision-free survival for all implants on 98.8 % at 10 years in renal transplant patients . In contrast, recent evidence suggests that uncemented hip arthroplasty in renal transplant recipients have similar survivorship [5, 17, 30]. Ledford et al. used, in his collective of 15 THA in 10 lung transplant recipients, cementless implants . In our population, no THA dislocation or loosening of the implants were observed during follow-up.
A limitation of our study includes small numbers of patients, midterm follow-up and its retrospective design.
In conclusion, THA can be safely and successfully performed even in lung transplant patients, provided a multidisciplinary approach can be granted.
AMIS, Anterior minimal invasive surgery; AVN, Avascular necrosis; BMD, Bone mineral density; BMI, Body mass index; CF, Cystic fibrosis; CIP, Ciprofloxacin; CLAD, Chronic lung allograft dysfunction; CMV, Cytomegalovirus; COPD, Chronic obstructive pulmonary disease; CYA, Cyclosporine A; F/U, Follow-up; FX, Fracture; HHS, Harris hip score; ICU, Intensive care unit; IMCU, Intermediate care unit; INN, Amoxicillin/Clavulanic acid; IPAH, Idiopathic pulmonary arterial hypertension; IV, Intravenous; LAM, Lymphangioleiomyomatosis; MER, Meropenem; MMF, Mycophenolate mofetil; MRI, Magnetic resonance imaging; PCP, Pneumocystis pneumonia; PRED, Prednisone; TAC, Tacrolimus; TEC, Teicoplanin; THA, Total hip arthroplasty; TZP, Piperacillin/Tazobactam; VAS, Visual analogue scale
JWS conceived of the study, carried out the acquisition of data, analysis and interpretation of data, and drafted the manuscript. CB an participated in the conception and design of the study, carried out analysis and interpretation of data, and helped to draft the manuscript. CD participated in in the conception and design of the study, carried out analysis and interpretation of data, and helped to draft the manuscript. CMLW conceived of the study, carried out the acquisition of data, analysis and interpretation of data, and helped to draft the manuscript. He is the senior author. All authors read and approved the final manuscript.
The authors declare that they have no competing interests.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Yusen RD et al. The registry of the international society for heart and lung transplantation: thirty-first adult lung and heart-lung transplant report--2014; focus theme: retransplantation. J Heart Lung Transplant. 2014;33(10):1009–24.View ArticlePubMedGoogle Scholar
- Cahill BC et al. Prevention of bone loss and fracture after lung transplantation: a pilot study. Transplantation. 2001;72(7):1251–5.View ArticlePubMedGoogle Scholar
- Demirors H et al. Effect of long-term steroid use on prognosis for patients with surgically treated avascular necrosis of the hip. Transplant Proc. 2002;34(6):2114–8.View ArticlePubMedGoogle Scholar
- Marston SB et al. Osteonecrosis of the femoral head after solid organ transplantation: a prospective study. J Bone Joint Surg Am. 2002;84-A(12):2145–51.PubMedGoogle Scholar
- Nowicki P, Chaudhary H. Total hip replacement in renal transplant patients. J Bone Joint Surg (Br). 2007;89(12):1561–6.View ArticleGoogle Scholar
- Vergidis P et al. Prosthetic joint infection in solid organ transplant recipients: a retrospective case–control study. Transpl Infect Dis. 2012;14(4):380–6.View ArticlePubMedGoogle Scholar
- Tannenbaum DA, Matthews LS, Grady-Benson JC. Infection around joint replacements in patients who have a renal or liver transplantation. J Bone Joint Surg Am. 1997;79(1):36–43.View ArticlePubMedGoogle Scholar
- Aris RM et al. Severe osteoporosis before and after lung transplantation. Chest. 1996;109(5):1176–83.View ArticlePubMedGoogle Scholar
- Aringer M et al. High turnover bone disease following lung transplantation. Bone. 1998;23(5):485–8.View ArticlePubMedGoogle Scholar
- Spira A et al. Osteoporosis and lung transplantation: a prospective study. Chest. 2000;117(2):476–81.View ArticlePubMedGoogle Scholar
- Leonard GR, Davis CM. Outcomes of total hip and knee arthroplasty after cardiac transplantation. J Arthroplasty. 2012;27(6):889–94.View ArticlePubMedGoogle Scholar
- Isono SS, Woolson ST, Schurman DJ. Total joint arthroplasty for steroid-induced osteonecrosis in cardiac transplant patients. Clin Orthop Relat Res. 1987;217:201–8.PubMedGoogle Scholar
- Ledford CK et al. Risk versus reward: total joint arthroplasty outcomes after various solid organ transplantations. J Arthroplasty. 2014;29(8):1548–52.View ArticlePubMedGoogle Scholar
- Aminata I et al. Perioperative morbidity and mortality of total hip replacement in liver transplant recipients: a 7-year single-center experience. Transplantation. 2012;94(11):1154–9.View ArticlePubMedGoogle Scholar
- Levitsky J, Te HS, Cohen SM. The safety and outcome of joint replacement surgery in liver transplant recipients. Liver Transpl. 2003;9(4):373–6.View ArticlePubMedGoogle Scholar
- Papagelopoulos PJ et al. Total joint arthroplasty in orthotopic liver transplant recipients. J Arthroplasty. 1996;11(8):889–92.View ArticlePubMedGoogle Scholar
- Chang JS et al. Cementless total hip arthroplasty in patients with osteonecrosis after kidney transplantation. J Arthroplasty. 2013;28(5):824–7.View ArticlePubMedGoogle Scholar
- Chmell SJ et al. Total hip replacement in patients with renal transplants. Arch Surg. 1983;118(4):489–95.View ArticlePubMedGoogle Scholar
- Deo S et al. Total hip replacement in renal transplant patients. J Bone Joint Surg (Br). 1995;77(2):299–302.Google Scholar
- Goffin E, Baertz G, Rombouts JJ. Long-term survivorship analysis of cemented total hip replacement (THR) after avascular necrosis of the femoral head in renal transplant recipients. Nephrol Dial Transplant. 2006;21(3):784–8.View ArticlePubMedGoogle Scholar
- Lieu D et al. Review article: total hip replacement in haemodialysis or renal transplant patients. J Orthop Surg (Hong Kong). 2014;22(3):393–8.Google Scholar
- Cheng EY et al. Total hip arthroplasty with cement after renal transplantation. Long-term results. J Bone Joint Surg Am. 1995;77(10):1535–42.PubMedGoogle Scholar
- Bucci JR et al. Hospitalizations for total hip arthroplasty after renal transplantation in the United States. Am J Transplant. 2002;2(10):999–1004.View ArticlePubMedGoogle Scholar
- Lim BH et al. Cementless total hip arthroplasty in renal transplant patients. Hip Int. 2012;22(5):516–20.View ArticlePubMedGoogle Scholar
- Angermeier EW et al. Complications of hip and knee joint replacement in solid-organ transplant patients. J Surg Orthop Adv. 2013;22(3):204–12.View ArticlePubMedGoogle Scholar
- Ledford CK et al. Outcomes of primary total joint arthroplasty after lung transplantation. J Arthroplasty. 2014;29(1):11–5.View ArticlePubMedGoogle Scholar
- Schuurmans MM et al. Practical approach to emergencies in lung transplant recipients: how we do it. Respiration. 2012;84(2):163–75.View ArticlePubMedGoogle Scholar
- Abbott KC et al. Hospitalizations for fractures after renal transplantation in the United States. Ann Epidemiol. 2001;11(7):450–7.View ArticlePubMedGoogle Scholar
- Meakin CJ, Hopson CN, First MR. Avascular (aseptic) necrosis of bone following renal transplantation. Int J Artif Organs. 1985;8(1):19–20.PubMedGoogle Scholar
- Piston RW et al. Osteonecrosis of the femoral head treated with total hip arthroplasty without cement. J Bone Joint Surg Am. 1994;76(2):202–14.PubMedGoogle Scholar